Azelnidipine prevents cardiac dysfunction in streptozotocin-diabetic rats by reducing intracellular calcium accumulation, oxidative stress and apoptosis

Cardiovascular Diabetology

Volumn 10, Issue , 2011, Pages

  Kain, Vasundhara ^a   Kumar, Sandeep ^a   Sitasawad, Sandhya L ^a  

^a NATIONAL CENTRE FOR CELL SCIENCE   (India)

Author keywords

Apoptosis; Azelnidipine; Ca2+ homeostasis; diabetic cardiomyopathy; Mitochondria; Oxidative stress

Indexed keywords

AZELNIDIPINE; PROTEIN BCL 2; PROTEIN P67; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE; RYANODINE RECEPTOR 2; STREPTOZOCIN; SUPEROXIDE; TROPONIN I; ANTIOXIDANT; ATP2A2 PROTEIN, RAT; AZETIDINE 2 CARBOXYLIC ACID; CALCIUM; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DRUG DERIVATIVE; NEUTROPHIL CYTOSOL FACTOR 67K; PHOSPHOPROTEIN; RYANODINE RECEPTOR; SARCOPLASMIC RETICULUM CALCIUM TRANSPORTING ADENOSINE TRIPHOSPHATASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CALCIUM CELL LEVEL; DIABETES MELLITUS; DIABETIC CARDIOMYOPATHY; HEART MUSCLE CELL; MALE; NONHUMAN; OXIDATIVE STRESS; RAT; SINGLE DRUG DOSE; STREPTOZOCIN DIABETES; ANIMAL; DRUG EFFECT; EXPERIMENTAL DIABETES MELLITUS; HEART CONTRACTION; HEART LEFT VENTRICLE FUNCTION; HEART MUSCLE; METABOLISM; PATHOLOGY; PATHOPHYSIOLOGY; TIME; WISTAR RAT;

ANIMALS; ANTIOXIDANTS; APOPTOSIS; AZETIDINECARBOXYLIC ACID; CALCIUM; CALCIUM CHANNEL BLOCKERS; DIABETES MELLITUS, EXPERIMENTAL; DIABETIC CARDIOMYOPATHIES; DIHYDROPYRIDINES; MALE; MYOCARDIAL CONTRACTION; MYOCARDIUM; OXIDATIVE STRESS; PHOSPHOPROTEINS; RATS; RATS, WISTAR; RYANODINE RECEPTOR CALCIUM RELEASE CHANNEL; SARCOPLASMIC RETICULUM CALCIUM-TRANSPORTING ATPASES; SUPEROXIDES; TIME FACTORS; TROPONIN I; VENTRICULAR DYSFUNCTION, LEFT; VENTRICULAR FUNCTION, LEFT;

EID: 80155123422     PISSN: None     EISSN: 14752840     Source Type: Journal    
DOI: 10.1186/1475-2840-10-97     Document Type: Article

References (50)

1. Rubler S, Dlugash J, Yuceoglu YZ, Kumral T, Branwood AW, Grishman A. New type of cardiomyopathy associated with diabetic glomerulosclerosis. Am J Cardiol 1972, 30(6):595-602. 10.1016/0002-9149(72)90595-4, 4263660.
2. Asmal AC, Leary WP, Thandroyen F. Diabetic heart disease. S Afr Med J 1980, 57(19):788-790.
3. Regan TJ. Congestive heart failure in the diabetic. Annu Rev Med 1983, 34:161-168. 10.1146/annurev.me.34.020183.001113, 6344754.
4. Hamby RI, Zoneraich S, Sherman L. Diabetic cardiomyopathy. Jama 1974, 229(13):1749-1754. 10.1001/jama.229.13.1749, 4278055.
5. Regan TJ, Lyons MM, Ahmed SS, Levinson GE, Oldewurtel HA, Ahmad MR, Haider B. Evidence for cardiomyopathy in familial diabetes mellitus. J Clin Invest 1977, 60(4):884-899. 372437, 893679.
6. Mahgoub MA, Abd-Elfattah AS. Diabetes mellitus and cardiac function. Mol Cell Biochem 1998, 180(1-2):59-64.
7. Pierce GN, Russell JC. Regulation of intracellular Ca2+ in the heart during diabetes. Cardiovasc Res 1997, 34(1):41-47. 10.1016/S0008-6363(97)00010-2, 9217871.
8. Choi KM, Zhong Y, Hoit BD, Grupp IL, Hahn H, Dilly KW, Guatimosim S, Lederer WJ, Matlib MA. Defective intracellular Ca(2+) signaling contributes to cardiomyopathy in Type 1 diabetic rats. Am J Physiol Heart Circ Physiol 2002, 283(4):H1398-1408.
9. Cai L, Wang Y, Zhou G, Chen T, Song Y, Li X, Kang YJ. Attenuation by metallothionein of early cardiac cell death via suppression of mitochondrial oxidative stress results in a prevention of diabetic cardiomyopathy. J Am Coll Cardiol 2006, 48(8):1688-1697.
10. Cai L. Suppression of nitrative damage by metallothionein in diabetic heart contributes to the prevention of cardiomyopathy. Free Radic Biol Med 2006, 41(6):851-861. 10.1016/j.freeradbiomed.2006.06.007, 16934665.
11. Boudina S, Abel ED. Diabetic cardiomyopathy revisited. Circulation 2007, 115(25):3213-3223. 10.1161/CIRCULATIONAHA.106.679597, 17592090.
12. Teshima Y, Takahashi N, Saikawa T, Hara M, Yasunaga S, Hidaka S, Sakata T. Diminished expression of sarcoplasmic reticulum Ca(2+)-ATPase and ryanodine sensitive Ca(2+)Channel mRNA in streptozotocin-induced diabetic rat heart. J Mol Cell Cardiol 2000, 32(4):655-664. 10.1006/jmcc.2000.1107, 10756121.
13. Ganguly PK, Pierce GN, Dhalla KS, Dhalla NS. Defective sarcoplasmic reticular calcium transport in diabetic cardiomyopathy. Am J Physiol 1983, 244(6):E528-535.
14. Rodrigues B, Rosa K, Medeiros A, Schaan B, Brum P, De Angelis K, Irigoyen M. Hyperglycemia can delay left ventricular dysfunction but not autonomic damage after myocardial infarction in rodents. Cardiovasc Diabetol 2011, 10(1):26. 10.1186/1475-2840-10-26, 3084163, 21470409.
15. Isabelle M, Vergeade A, Moritz F, Dautreaux B, Henry JP, Lallemand F, Richard V, Mulder P, Thuillez C, Monteil C. NADPH oxidase inhibition prevents cocaine-induced up-regulation of xanthine oxidoreductase and cardiac dysfunction. J Mol Cell Cardiol 2007, 42(2):326-332. 10.1016/j.yjmcc.2006.11.011, 17217956.
16. Heymes C, Bendall JK, Ratajczak P, Cave AC, Samuel JL, Hasenfuss G, Shah AM. Increased myocardial NADPH oxidase activity in human heart failure. J Am Coll Cardiol 2003, 41(12):2164-2171. 10.1016/S0735-1097(03)00471-6, 12821241.
17. Li JM, Gall NP, Grieve DJ, Chen M, Shah AM. Activation of NADPH oxidase during progression of cardiac hypertrophy to failure. Hypertension 2002, 40(4):477-484. 10.1161/01.HYP.0000032031.30374.32, 12364350.
18. Xiao L, Pimentel DR, Wang J, Singh K, Colucci WS, Sawyer DB. Role of reactive oxygen species and NAD(P)H oxidase in alpha(1)-adrenoceptor signaling in adult rat cardiac myocytes. Am J Physiol Cell Physiol 2002, 282(4):C926-934.
19. Zhao K, Zhao GM, Wu D, Soong Y, Birk AV, Schiller PW, Szeto HH. Cell-permeable peptide antioxidants targeted to inner mitochondrial membrane inhibit mitochondrial swelling, oxidative cell death, and reperfusion injury. J Biol Chem 2004, 279(33):34682-34690. 10.1074/jbc.M402999200, 15178689.
20. Nagy N, Malik G, Tosaki A, Ho YS, Maulik N, Das DK. Overexpression of glutaredoxin-2 reduces myocardial cell death by preventing both apoptosis and necrosis. J Mol Cell Cardiol 2008, 44(2):252-260. 10.1016/j.yjmcc.2007.08.021, 18076901.
21. Wold LE, Ceylan-Isik AF, Fang CX, Yang X, Li SY, Sreejayan N, Privratsky JR, Ren J. Metallothionein alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of Ca2+ cycling proteins, NADPH oxidase, poly(ADP-Ribose) polymerase and myosin heavy chain isozyme. Free Radic Biol Med 2006, 40(8):1419-1429. 10.1016/j.freeradbiomed.2005.12.009, 16631532.
22. Wendt MC, Daiber A, Kleschyov AL, Mulsch A, Sydow K, Schulz E, Chen K, Keaney JF, Lassegue B, Walter U, et al. Differential effects of diabetes on the expression of the gp91phox homologues nox1 and nox4. Free Radic Biol Med 2005, 39(3):381-391. 10.1016/j.freeradbiomed.2005.03.020, 15993337.
23. Shen X, Zheng S, Metreveli NS, Epstein PN. Protection of cardiac mitochondria by overexpression of MnSOD reduces diabetic cardiomyopathy. Diabetes 2006, 55(3):798-805. 10.2337/diabetes.55.03.06.db05-1039, 16505246.
24. Boudina S, Sena S, Theobald H, Sheng X, Wright JJ, Hu XX, Aziz S, Johnson JI, Bugger H, Zaha VG, et al. Mitochondrial energetics in the heart in obesity-related diabetes: direct evidence for increased uncoupled respiration and activation of uncoupling proteins. Diabetes 2007, 56(10):2457-2466. 10.2337/db07-0481, 17623815.
25. Privratsky JR, Wold LE, Sowers JR, Quinn MT, Ren J. AT1 blockade prevents glucose-induced cardiac dysfunction in ventricular myocytes: role of the AT1 receptor and NADPH oxidase. Hypertension 2003, 42(2):206-212. 10.1161/01.HYP.0000082814.62655.85, 12847113.
26. Kain V, Kumar S, Puranik AS, Sitasawad SL. Azelnidipine protects myocardium in hyperglycemia-induced cardiac damage. Cardiovasc Diabetol 2010, 9:82. 10.1186/1475-2840-9-82, 3004822, 21118576.
27. Maggi CA, Meli A. Suitability of urethane anesthesia for physiopharmacological investigations in various systems. Part 2: Cardiovascular system. Experientia 1986, 42(3):292-297. 10.1007/BF01942510, 3007197.
28. Kajstura J, Fiordaliso F, Andreoli AM, Li B, Chimenti S, Medow MS, Limana F, Nadal-Ginard B, Leri A, Anversa P. IGF-1 overexpression inhibits the development of diabetic cardiomyopathy and angiotensin II-mediated oxidative stress. Diabetes 2001, 50(6):1414-1424. 10.2337/diabetes.50.6.1414, 11375343.
29. Ren J, Wold LE. Measurement of Cardiac Mechanical Function in Isolated Ventricular Myocytes from Rats and Mice by Computerized Video-Based Imaging. Biol Proced Online 2001, 3:43-53. 10.1251/bpo22, 145545, 12734580.
30. Kumar S, Kain V, Sitasawad SL. Cardiotoxicity of calmidazolium chloride is attributed to calcium aggravation, oxidative and nitrosative stress, and apoptosis. Free Radic Biol Med 2009, 47(6):699-709. 10.1016/j.freeradbiomed.2009.05.028, 19497364.
31. Murugavel P, Pari L, Sitasawad SL, Kumar S. Cadmium induced mitochondrial injury and apoptosis in vero cells: protective effect of diallyl tetrasufide from garlic. Int J Biochem Cell Biol 2007, 39(1):161-170. 10.1016/j.biocel.2006.07.013, 16971165.
32. Trost SU, Belke DD, Bluhm WF, Meyer M, Swanson E, Dillmann WH. Overexpression of the sarcoplasmic reticulum Ca(2+)-ATPase improves myocardial contractility in diabetic cardiomyopathy. Diabetes 2002, 51(4):1166-1171. 10.2337/diabetes.51.4.1166, 11916940.
33. Bidasee KR, Dincer UD, Besch HR. Ryanodine receptor dysfunction in hearts of streptozotocin-induced diabetic rats. Mol Pharmacol 2001, 60(6):1356-1364.
34. Shao CH, Rozanski GJ, Patel KP, Bidasee KR. Dyssynchronous (non-uniform) Ca2+ release in myocytes from streptozotocin-induced diabetic rats. J Mol Cell Cardiol 2007, 42(1):234-246. 10.1016/j.yjmcc.2006.08.018, 17027851.
35. Oizumi K, Nishino H, Koike H, Sada T, Miyamoto M, Kimura T. Antihypertensive effects of CS-905, a novel dihydropyridine Ca++ channel blocker. Jpn J Pharmacol 1989, 51(1):57-64. 10.1254/jjp.51.57, 2810942.
36. Matsui T, Yamagishi S, Nakamura K, Inoue H. Azelnidipine, a New Long-acting Calcium-channel Blocker, Inhibits Tumour Necrosis Factor--induced Monocyte Chemoattractant Protein-1 Expression in Endothelial Cells. The Journal of International Medical Research 2006, 34(6):671-675.
37. Fukao K, Shimada K, Hiki M, Kiyanagi T, Hirose K, Kume A, Ohsaka H, Matsumori R, Kurata T, Miyazaki T, et al. Effects of calcium channel blockers on glucose tolerance, inflammatory state, and circulating progenitor cells in non-diabetic patients with essential hypertension: a comparative study between Azelnidipine and amlodipine on Glucose tolerance and ENdothelial function - a crossover Trial (AGENT). Cardiovasc Diabetol 2011, 10(1):79. 10.1186/1475-2840-10-79, 3179711, 21906391.
38. Abe M, Maruyama N, Okada K, Matsumoto S, Matsumoto K, Soma M. Additive antioxidative effects of azelnidipine on angiotensin receptor blocker olmesartan treatment for type 2 diabetic patients with albuminuria. Hypertens Res 2011, 34(8):935-941. 10.1038/hr.2011.67, 21654755.
39. Ohyama T, Sato K, Kishimoto K, Yamazaki Y, Horiguchi N, Ichikawa T, Kakizaki S, Takagi H, Izumi T, Mori M. Azelnidipine is a calcium blocker that attenuates liver fibrosis and may increase antioxidant defence. Brit J Pharmacol 2011, no-no.
40. Sarkar K, Mehta JL. Apoptosis in Atherosclerosis: Virtue or Vice. Current Cardiology Reviews 2005, 1:141-152.
41. Oliveira PJ. Cardiac mitochondrial alterations observed in hyperglycaemic rats--what can we learn from cell biology?. Curr Diabetes Rev 2005, 1(1):11-21. 10.2174/1573399052952578, 18220578.
42. Schaffer SW, Croft CB, Solodushko V. Cardioprotective effect of chronic hyperglycemia: effect on hypoxia-induced apoptosis and necrosis. Am J Physiol Heart Circ Physiol 2000, 278(6):H1948-1954.
43. Border WA, Brees D, Noble NA. Transforming growth factor-beta and extracellular matrix deposition in the kidney. Contrib Nephrol 1994, 107:140-145.
44. Verma S, Maitland A, Weisel RD, Li SH, Fedak PW, Pomroy NC, Mickle DA, Li RK, Ko L, Rao V. Hyperglycemia exaggerates ischemia-reperfusion-induced cardiomyocyte injury: reversal with endothelin antagonism. J Thorac Cardiovasc Surg 2002, 123(6):1120-1124. 10.1067/mtc.2002.121973, 12063458.
45. Ren J, Davidoff AJ. Diabetes rapidly induces contractile dysfunctions in isolated ventricular myocytes. Am J Physiol 1997, 272(1 Pt 2):H148-158.
46. Norby FL, Wold LE, Duan J, Hintz KK, Ren J. IGF-I attenuates diabetes-induced cardiac contractile dysfunction in ventricular myocytes. Am J Physiol Endocrinol Metab 2002, 283(4):E658-666.
47. Ye G, Metreveli NS, Ren J, Epstein PN. Metallothionein prevents diabetes-induced deficits in cardiomyocytes by inhibiting reactive oxygen species production. Diabetes 2003, 52(3):777-783. 10.2337/diabetes.52.3.777, 12606520.
48. Liu X, Takeda N, Dhalla NS. Troponin I phosphorylation in heart homogenate from diabetic rat. Biochim Biophys Acta 1996, 1316(2):78-84.
49. Bers DM. Cardiac excitation-contraction coupling. Nature 2002, 415(6868):198-205. 10.1038/415198a, 11805843.
50. Guo Z, Xia Z, Jiang J, McNeill JH. Downregulation of NADPH oxidase, antioxidant enzymes, and inflammatory markers in the heart of streptozotocin-induced diabetic rats by N-acetyl-L-cysteine. Am J Physiol Heart Circ Physiol 2007, 292(4):H1728-1736.